![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, September 12, 2019 11:02:17 PM
On the one hand, it seems there is some type of non-binding agreement that was reached.
Near as I can tell, that non-binding agreement calls for a $50M payment upon product launch, and royalties of 50%, although 50% of what was not clear.
In addition, the physician who spoke after Pourhassan was clear and eloquent.
On the other hand, Pourhassan's presentation was substandard, and not what one would hope for in a CEO.
Not only was Pourhassan's voice muffled (unlike the physician who spoke after him, who came across very clearly), but he spoke much too quickly.
In addition, the history lesson was wasted time, in my opinion, as most were waiting to hear about the non-binding agreement and possible merger that was telegraphed in the last paid interview.
As for the agreement, Pourhassan could have been more clear as to the partner and the terms.
Even if Pourhassan could not disclose the name of the partner, he could have indicated if the partner was BP, a biotech, or some hints about the type and size of the company in question.
In addition, would it really be so hard to describe the terms more clearly?
Does Cytodyn get $50M when Leronlimab is approved, when it gets an order, or when sales reach a certain level?
And what, exactly, is the agreement regarding royalties?
Does Cytodyn get 50% of the gross sales, 50% of the gross profits, 50% of the net profits, or none of the above.
Pourhassan also mentioned six weeks.
But six weeks to what?
A signed agreement, a first payment, or something different altogether?
I understand Pourhassan is not a gifted speaker.
However, he could have practiced his presentation, or even used a teleprompter, so what he said came out clear and coherent, rather than muffled and confusing.
So I continue to be impressed with the science, and frustrated by the CEO.
Apparently many shareholders are frustrated as well as the lukewarm reception given to the salary vote was hardly a vote of confidence. I suspect without the shares of the other directors, that vote would have lost.
So, as always seems to be the case, we are left in a state of uncertainty as our CEO cannot present the facts in a clear and coherent fashion.
Frustrating, to be sure.
My great hope is that Cytodyn partners with a company who promptly replaces Pourhassan with someone who has the knowledge, background, and experience to take this very promising company to the promised land.
LM
Recent CYDY News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 09:15:10 PM
- Form SC TO-I - Tender offer statement by Issuer • Edgar (US Regulatory) • 06/03/2024 09:10:56 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/06/2024 09:17:30 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/06/2024 09:16:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 09:09:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2024 02:30:20 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/01/2024 10:16:47 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/01/2024 10:15:34 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/22/2024 10:16:11 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/22/2024 05:15:08 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 02:00:24 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 10:31:57 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/29/2024 10:22:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2024 01:40:14 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/19/2024 10:15:35 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/16/2024 10:16:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:04:57 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:04:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:02:59 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:02:30 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM